Electrophoretics Limited

Other

Deutsches Krebsforschungszentrum

Ruprecht-karls-universität

King's College London

Proteome Sciences Plc

Karsten Kuhn

Andrew Hugin Thompson

Stefan Kienle

Christian Hamon

Ian Hugo Pike

Juergen Schaefer

Peter Schulz-Knappe

Thomas Neumann

Christian Baumann

Michael Platten

Malcolm Andrew Ward

Helen Louise Byers

Joseph M Sheridan

Jonathan R Heal

Petra Budde

William D O Hamilton

Richard Joubert

Simon Lovestone

Hans-Dieter Zucht

Petra Prefot

Gitte Boehm

Christiane Opitz

Jürgen Schäfer

Jules Westbrook

Abdul Hye

Joseph Schwarz

Markus Meyer

Schafer Juergen

Josef Schwarz

Gitte Böhm

Wolfgang Becker

Sasa Koncarevic

Nikolai Woellmer

Dieter Reuschling

Harald Legner

Stephen Lynham

Stephan Jung

Thorsten Prinz

Stefan Selzer

Nikolai Wollmer

Nikolai WÖLLMER

Malcom Ward

Stefan Kielne

Tryptophan degradation is a key metabolic pathway controlling immune reactions and evidence suggests that during cancer progression generation of tryptophan metabolites may be fundamental for immune escape promoting the malignant phenotype of cancer cells in an autocrine fashion. The present invention relates to methods of measuring mass tag labelled tryptophan and metabolites thereof and methods using the labelled molecules for monitoring in a subject the effectiveness of a treatment and of disease recurrence after treatment, for stratifying patients and for diagnosing suppression of an immune response in a subject.

Isotopic methods for measurement of tryptophan and metabolites thereof

Provided is a method of assaying for an analyte, including combining a test sample having the analyte, with a calibration sample having at least two different aliquots of the analyte, each aliquot having a different known quantity of the analyte. The test sample and each aliquot are differentially labeled with one or more isobaric mass labels each with a mass spectrometrically distinct mass marker group, such that the test sample and each aliquot of the calibration sample can be distinguished by mass spectrometry. The method further includes determining by mass spectrometry the quantity of analyte in the test sample and in each aliquot, and calibrating the quantity of analyte in the test sample against known and determined quantities of analytes in the aliquots.

Mass spectrometric quantitation

The present invention provides 2-Methyl-amino-3-[(4-fluorophenyl)carbonyl]indolizine-1-carboxamide of formula (I) or a pharmaceutically acceptable salt thereof; and its therapeutic uses in the treatment of neurodegenerative disorders, in particular tauopathies and most preferably in the treatment of Alzheimer's disease.

Casein kinase 1 delta inhibitor

The present invention provides a method for labelling one or more analytes in a sample, the method comprising: a) contacting the sample with one or more bifunctional linker reagents having the general formula Re-L-Re, wherein Reis a first reactive group, Lis a linker moiety and Reis a second reactive group, wherein Rereacts with an analyte to form a modified analyte; and b) contacting the sample with one or more mass labels, wherein Reof the bifunctional linker attached to the analyte reacts with a mass label to form a labelled analyte, wherein each mass label is relatable to an analyte by mass spectrometry.

Mass labels

The present invention relates to a set of two or more mass labels. Each mass label comprises: X-L-M-Re; X is a reporter moiety having exact mass; L is a bond cleavable by collision in a mass spectrometer; M is a mass modifier; Re is a) a reactive functionality for attaching the mass label to an analyte or b) the analyte. Each mass label in the set has the same integer mass; wherein the set comprises two or more subsets of mass labels, each subset comprising one or more mass labels; wherein, when the subset comprises two or more mass labels, the exact mass of the reporter moiety X of each mass label in the subset is different from the exact mass of the reporter moiety X of the mass labels in the same subset and in all other subsets; each mass label is distinguishable by mass spectrometry.

Isobaric mass labels

A reactive mass label for labelling a biological molecule for detection by mass spectrometry, which label comprises a reactive functionality for labelling thiol groups or carbonyl groups. Also provided is a reactive mass label for labelling a biological molecule for detection by mass spectrometry, wherein the mass label comprises the following structure:X-L-M-S&#x2014;Rewherein X is a mass marker moiety, L is a cleavable linker, M is a mass normalization moiety, S is a mass series modifying group comprising the following group: wherein J is C&#x2550;O, K is NH, and n is 2 or J and K are both CHand n is 1, and wherein m is at least 1; and Re is a reactive functionality for attaching the mass label to a biological molecule.

A mass label for labelling and detecting a biological molecule by mass spectroscopy, which label comprises the following structure: X-L-M wherein X is a mass marker moiety comprising the following group: formula (I), wherein the cyclic unit is aromatic or aliphatic and comprises from 0-3 double bonds independently between any two adjacent atoms; each Z is independently N, N(R), C(R), CO, CO(R), C(R), O or S; X is N, C or C(R); each Ris independently H, a substituted or unsubstituted straight or branched C-Calkyl group, a substituted or unsubstituted aliphatic cyclic group, a substituted or unsubstituted aromatic group or a substituted or unsubstituted heterocyclic group; and y is an integer from 0-10, L is a cleavable linker comprising an amide bond and M is a mass normalization moiety. 

Reactive mass labels

Provided is a method for characterizing a molecule by mass spectrometry, which molecule comprises one or more free amino groups, which method comprises: (a) reacting one or more free amino groups in the molecule with a mass tag reagent comprising a reactive functionality capable of reacting with an amino group, and a tertiary amino group linked to the reactive functionality; and (b) characterizing the molecule by mass spectrometry.

Labeling agents for mass spectrometry comprising tertiary amines

Methods and compositions relating to Alzheimer's disease are provided. Specifically, proteins that are differentially expressed in the Alzheimer's disease state relative to their expression in the normal state are provided. Proteins associated with Alzheimer's disease are identified and described. Methods of diagnosis of Alzheimer's disease using the differentially expressed proteins are also provided, as are methods for the identification and therapeutic use of compounds for the prevention and treatment of Alzheimer's disease.

Methods of diagnosing Alzheimer's disease

Provided is a set of two or more mass labels, each label in the set comprising a mass marker moiety attached via a cleavable linker having at least one amide bond to a mass normalization moiety, wherein the aggregate mass of each label in the set may be the same or different and the mass of the mass marker moiety of each label in the set may be the same or different, and wherein in any group of labels within the set having a mass marker moiety of a common mass each label has an aggregate mass different from all other labels in that group, and wherein in any group of labels within the set having a common aggregate mass each label has a mass marker moiety having a mass different from that of all other mass marker moieties in that group, such that all of the mass labels in the set are distinguishable from each other by mass spectrometry, and wherein the mass marker moiety comprises an amino acid and the mass normalization moiety comprises an amino acid.

Provided is a method for characterizing an analyte by matrix assisted laser desorption ionization (MALDI) mass spectrometry, which method comprises:

Method for charcterising analytes

Growing community of inventors

Hofheim am Taunus, Germany

Karsten Kuhn